Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $45.00 | Buy | Craig Hallum |
| 12/5/2024 | $38.00 → $37.00 | Buy → Neutral | Goldman |
| 11/15/2024 | $50.00 | Outperform | Wolfe Research |
| 10/16/2024 | $43.00 | Buy | UBS |
| 10/10/2024 | $40.00 | Buy | Guggenheim |
| 2/23/2024 | $30.00 → $33.00 | Buy | Needham |
| 1/18/2023 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00
Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously
Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00
SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)
10-Q - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (NASDAQ: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The prostate PAM50 biomarker is currently available for Research Use Only on the Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. The new findings were shared today by Daniel Spratt, M.D., University Hospitals Seidman Can
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 25, 2025 /PRNewswire/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in four Americans will be over 65 by 2060[1]. Gene therapy approvals continue accelerating as the FDA recently approved breakthrough treatments targeting rare diseases[2], while AI-powered diagnostic platforms are transforming how clinicians detect conditions before symptoms appear[3]. These market-wide trends are positioning early-stage companies across diagnostics, gene therapy, and personalized medicine for significant growth
Findings are among nine Decipher-focused abstracts being presented at annual conference Veracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting of the American Society for Radiation Oncology. The findings were derived using Veracyte's Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. The study is among nine Decipher-focused abstracts—including six selected for podium presentations—in prostate cancer that will be presented at the conference, being
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. "Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth," said Marc Stapley, Veracyte's chief executive officer. "This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for in
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5gqvvmtt. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
SC 13G - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)